Status:
UNKNOWN
Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.
Lead Sponsor:
Instituto Jalisciense de Cancerologia
Collaborating Sponsors:
Instituto Mexicano del Seguro Social
University of Guadalajara
Conditions:
Multiple Sclerosis, Relapsing-Remitting
Eligibility:
All Genders
18-65 years
Brief Summary
HLA-DRB1 \* Gene and some genes involved in inflammation and immunity (IL-7R, GPC5, CTSS) have been linked to risk of MS and the response to treatment with immunomodulators. This research aims to esti...
Detailed Description
Genes HLA-DRB1 \* and some genes involved in inflammation and immunity have been linked to risk of MS and the response to treatment with immunomodulators. The HLA-DRB1 \* genes have been associated w...
Eligibility Criteria
Inclusion
- Inclusion Criteria for Cases:
- Subjects with multiple sclerosis
- 18 and over
- EDSS less than 5
- Signed informed consent
- Inclusion Criteria for Controls:
- Healthy subjects
- 18 and over
- Signed informed consent
- Exclusion Criteria for Cases:
- Mental retardation
- Withdrawal of consent
- No immunomodulatory treatment
- Exclusion Criteria for Controls:
- Mental retardation
- Withdrawal of consent
Exclusion
Key Trial Info
Start Date :
August 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2016
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT02769767
Start Date
August 1 2012
End Date
December 1 2016
Last Update
May 12 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Jalisciense de Cancerología
Guadalajara, Jalisco, Mexico, 44280